| Title |
Alzheimer's disease and blood-based biomarkers – potential contexts of use
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, July 2018
|
| DOI | 10.2147/ndt.s172285 |
| Pubmed ID | |
| Authors |
Martina Zvěřová |
| Abstract |
Alzheimer's disease (AD) is an irreversible, incurable, progressive neurodegenerative illness, where dementia symptoms gradually worsen over a number of years. The research of validated biomarkers for AD is essential to improve diagnosis and accelerate the development of new therapies. Biochemical markers including neuroimaging could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment, and be used to detect the efficacies of disease-modifying therapies. Established biomarkers of AD from cerebrospinal fluid and neuroimaging are highly accurate, but barriers to clinical implementation exist. The focus on blood-based AD biomarkers has grown exponentially during the past few decades. An ideal diagnostic test for AD should be noninvasive and easily applicable. Clinical cost-effectiveness also needs to be established. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 94 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 19% |
| Student > Bachelor | 13 | 14% |
| Student > Ph. D. Student | 10 | 11% |
| Student > Doctoral Student | 6 | 6% |
| Researcher | 6 | 6% |
| Other | 13 | 14% |
| Unknown | 28 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 12 | 13% |
| Biochemistry, Genetics and Molecular Biology | 8 | 9% |
| Engineering | 8 | 9% |
| Medicine and Dentistry | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 6% |
| Other | 25 | 27% |
| Unknown | 29 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2018.
All research outputs
#19,951,180
of 25,385,509 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,192
of 3,131 outputs
Outputs of similar age
#250,846
of 341,606 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#41
of 83 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,606 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.